Investigating new therapies for acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Research Project
This study is looking to find better treatments for people with acute myeloid leukemia (AML) by using special models made from patients' own cancer cells, which will help researchers understand how different genetic changes in AML respond to various therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10881943 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for patients with acute myeloid leukemia (AML) by utilizing genetically defined patient-derived xenograft (PDX) models. These models help researchers understand the molecular characteristics of AML and develop targeted therapies aimed at specific genetic alterations. By analyzing thousands of AML samples and their responses to various treatments, the project aims to identify effective therapeutic strategies that could enhance patient outcomes. The research seeks to overcome current limitations in therapy development by creating a comprehensive library of well-characterized AML PDX models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with specific genetic mutations.
Not a fit: Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with AML.
How similar studies have performed: Previous research has shown promise in using genetically defined models to develop targeted therapies for various cancers, indicating a potential for success in this approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Carroll, Martin — University of Pennsylvania
- Study coordinator: Carroll, Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.